| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 24.01.
| Recent 52-Week High Exceeded in Shares of Progenics Pharmaceuticals | | 4 | SmarTrend |
| 19.01.
| Shares of Progenics Pharmaceuticals Rise Above Previous 52-Week High | | 3 | SmarTrend |
| 06.01.
| Progenics Pharmaceuticals Shares Up 29.2% Since SmarTrend's Buy Recommendation | | 2 | SmarTrend |
| 20.12.
| Salix, Progenics Shares Rise On Positive Constipation Drug Study Results | | 68 | AFX News |
| WASHINGTON (dpa-AFX) - Shares of Salix Pharmaceuticals Ltd. (SLXP) and
Progenics Pharmaceuticals Inc. (PGNX) rose on Tuesday, after Salix reported a
successful late-stage trial of oral methylnaltrexone...
Mehr lesen zu:
Salix, Progenics Shares Rise On Positive Constipation Drug Study Results | |
| 20.12.
| Best Relative Performance in the Healthcare Sector Detected in Shares of Progenics Pharmaceuticals | | - | SmarTrend |
| 20.12.
| Notable Call Options Activity in Progenics Pharmaceuticals | | - | Benzinga.com |
| 20.12.
| Salix, Progenics Report Results Of Phase 3 Trial Of Oral Methylnaltrexone | | 39 | AFX News |
| WASHINGTON (dpa-AFX) - Salix Pharmaceuticals, Ltd. (SLXP) and Progenics
Pharmaceuticals, Inc. (PGNX) announced the successful outcome of the Phase 3
trial to assess the efficacy and safety...
Mehr lesen zu:
Salix, Progenics Report Results Of Phase 3 Trial Of Oral Methylnaltrexone | |
| 20.12.
| Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation | | 36 | Business Wire |
| NDA Submission Targeted for Mid 2012
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals,
Inc. (NASDAQ:PGNX) today announced the...
Mehr lesen zu:
Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation | |
| 23.09.
| Progenics (PGNX) Updates on PSMA ADC Phase 1; Drug Generally Well Tolerated | | 2 | StreetInsider.com |
| 30.08.
| Progenics (PGNX), Salix (SLXP) sNDA for RELISTOR Accepted by FDA; PDUFA Date Set | | 1 | StreetInsider.com |
| 30.08.
| Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR® in Patients with Non-Cancer Pain | | 36 | Business Wire |
| – PDUFA Action Date is April 27, 2012 –
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and Salix Pharmaceuticals,
Ltd. (NASDAQ:SLXP) today announced that...
Mehr lesen zu:
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR® in Patients with Non-Cancer Pain | |
